99 results on '"O'Cearbhaill R"'
Search Results
2. 317 Feasibility of an outpatient 12-step desensitization for patients with history of carboplatin hypersensitivity reactions (HSR) undergoing retreatment with carboplatin for recurrent ovarian or endometrial cancer
3. 295 Ovarian cancer care delivery: diversity in public perception and access to care
4. 82 Identification of neoantigens from non-primary tumor tissue in patients with recurrent ovarian cancer by sequencing and subsequent HLA ligand mass spectrometry
5. 38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results
6. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013
7. 46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor
8. O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results
9. 177 Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
10. Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation
11. 294 Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19
12. P122 VATS can be used to effectively triage women with ovarian cancer and moderate to large pleural effusions to PDS or NACT/IDS
13. 317 Feasibility of an outpatient 12-step desensitization for patients with history of carboplatin hypersensitivity reactions (HSR) undergoing retreatment with carboplatin for recurrent ovarian or endometrial cancer
14. 295 Ovarian cancer care delivery: diversity in public perception and access to care
15. 82 Identification of neoantigens from non-primary tumor tissue in patients with recurrent ovarian cancer by sequencing and subsequent HLA ligand mass spectrometry
16. 38 Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: final results
17. Pharmacokinetic analysis of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer
18. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma
19. Epidural anesthesia is associated with improved overall survival in patients undergoing primary debulking surgery for ovarian cancer
20. Comparison of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen
21. Impact of adjuvant chemotherapy in patients with FIGO stage I endometrioid ovarian carcinoma in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013
22. Comparison of outcomes in optimally-cytoreduced ovarian cancer patients receiving postoperative intraperitoneal chemotherapy vs intravenous dose-dense chemotherapy without bevacizumab
23. Cited rationale for variance in use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian, fallopian tube, and primary peritoneal carcinoma
24. The optimal primary management of bulky stage IIIC ovarian, fallopian tube, and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
25. Intraperitoneal chemotherapy outcomes following interval cytoreductive surgery for advanced-stage ovarian cancer at a comprehensive cancer center
26. Interval cytoreductive surgical outcome following administration of standard versus dose-dense neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
27. The impact of intraoperative tumor fragmentation or morcellation in patients with early-stage uterine leiomyosarcoma
28. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer
29. The impact of intraoperative tumor fragmentation or morcellation in patients with early-stage uterine leiomyosarcoma
30. Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer.
31. CA125 response to bevacizumab in recurrent ovarian cancer.
32. Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
33. 8055 The impact of prophylactic prolonged carboplatin infusion on risk of hypersensitivity reactions during carboplatin retreatment in epithelial ovarian cancer
34. Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC)
35. Evaluation of the role of aromatase inhibitors (AIs) in the treatment of uterine leiomyosarcoma (uLMS)
36. Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation
37. Evaluation of carboplatin dosage based on a body surface area adjusted 4-variable modification of diet in renal disease (MDRD) equation
38. Pulmonary epithelioid trophoblastic tumour: a case report
39. Estimating the real cost of adjuvant (adj) trastuzumab (T) in patients (pts) with HER-2+ (H+) early stage breast cancer (ESBC): Potential impact of reduced use of expensive oncology drugs (EOD) in metastatic breast cancer (MBC)
40. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer
41. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
42. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
43. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
44. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
45. Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
46. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
47. Immunotherapy toxicities: An SGO clinical practice statement.
48. Safety and efficacy of an outpatient 12-step desensitization protocol for antineoplastic agents.
49. Depletion of high-content CD14 + cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
50. Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.